iSpecimen Appoints Eric Langlois as Chief Revenue Officer
Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company’s…
ISP
iSpecimen to Participate in the Sequire Biotechnology Conference on February 2, 2023
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on January 25, 2023
LEXINGTON, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma…
Reverence Capital Partners Selects CAIS for Efficient Access to the Independent Wealth Channel
Alts Demand Continues to Rise Amid Challenging Market NEW YORK–(BUSINESS WIRE)–CAIS, the leading alternative investment…
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims…
iSpecimen Names Tracy Curley as Chief Executive Officer
Previously Appointed Interim CEO in September 2022 LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) —…
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a…
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal…
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody…
Quectel Continues to Drive Digital Transformation With Advanced Smart Module, Edge Intelligence and Machine Vision Technologies at CES 2023
LAS VEGAS–(BUSINESS WIRE)–CES – Quectel Wireless Solutions, a global IoT solutions provider, is today demonstrating…
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and…
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
Media Release COPENHAGEN, Denmark; January 2, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its…
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology…
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical…
Blaize Partners With Korea Telecom to Bring AI Transformation to Industrial and Enterprise Customers
Delivers AIoT (Artificial Intelligence of Things) edge technology for autonomous driving, robotics, and mobility AI…
A Memorandum of Cooperation Signed Among EdgeNext, Ajlan & Bros Holding Group, and Aofei International to Develop Digital Infrastructure in Saudi Arabia
BELLEVUE, Wash.–(BUSINESS WIRE)–#digitalinfrastructure—EdgeNext, Ajlan & Bros Holding Group, and Aofei International, three global leading companies…
Modifi Bio Announces Scientific Advisory Board
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trials NEW…